JP2014529629A5 - - Google Patents

Download PDF

Info

Publication number
JP2014529629A5
JP2014529629A5 JP2014528963A JP2014528963A JP2014529629A5 JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5 JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014528963 A JP2014528963 A JP 2014528963A JP 2014529629 A5 JP2014529629 A5 JP 2014529629A5
Authority
JP
Japan
Prior art keywords
chem
xaa
lys
linker
derivative according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014528963A
Other languages
English (en)
Japanese (ja)
Other versions
JP6126097B2 (ja
JP2014529629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/067364 external-priority patent/WO2013037690A1/en
Publication of JP2014529629A publication Critical patent/JP2014529629A/ja
Publication of JP2014529629A5 publication Critical patent/JP2014529629A5/ja
Application granted granted Critical
Publication of JP6126097B2 publication Critical patent/JP6126097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014528963A 2011-09-06 2012-09-06 Glp−1誘導体 Active JP6126097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11180265 2011-09-06
EP11180265.8 2011-09-06
US201161532323P 2011-09-08 2011-09-08
US61/532,323 2011-09-08
PCT/EP2012/067364 WO2013037690A1 (en) 2011-09-06 2012-09-06 Glp-1 derivatives

Publications (3)

Publication Number Publication Date
JP2014529629A JP2014529629A (ja) 2014-11-13
JP2014529629A5 true JP2014529629A5 (enExample) 2015-10-01
JP6126097B2 JP6126097B2 (ja) 2017-05-10

Family

ID=47882647

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528963A Active JP6126097B2 (ja) 2011-09-06 2012-09-06 Glp−1誘導体

Country Status (6)

Country Link
US (2) US9758560B2 (enExample)
EP (1) EP2753642B8 (enExample)
JP (1) JP6126097B2 (enExample)
CN (2) CN107266558A (enExample)
ES (1) ES2626013T3 (enExample)
WO (1) WO2013037690A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物
EP2846823B1 (en) * 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
DK3004155T3 (da) * 2013-05-28 2022-01-03 Takeda Pharmaceuticals Co Peptidforbindelse
WO2015155151A1 (en) * 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
JP2018012644A (ja) * 2014-11-26 2018-01-25 武田薬品工業株式会社 ペプチド化合物
PL3448416T3 (pl) * 2016-04-28 2022-11-07 Novo Nordisk A/S Semaglutyd w schorzeniach sercowo-naczyniowych
EP3467106B1 (en) 2016-05-24 2025-07-09 Takeda Pharmaceutical Company Limited Peptide compound
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
CN113214382B (zh) * 2018-04-19 2024-01-19 杭州先为达生物科技股份有限公司 酰化的glp-1衍生物
WO2021136223A1 (en) 2019-12-31 2021-07-08 Beijing Ql Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
PT4097099T (pt) 2020-02-07 2024-07-19 Gasherbrum Bio Inc Agonistas heterocíclicos de glp-1
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN113292646B (zh) * 2020-05-29 2022-05-13 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses
CN114874314B (zh) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 一种高表达glp-1类似物的重组工程菌及其构建方法
EP4490155A1 (en) 2022-03-09 2025-01-15 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN114621340B (zh) * 2022-03-11 2022-09-23 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
EP4323413A4 (en) 2022-03-30 2025-10-15 Beijing Ql Biopharmaceutical Co Ltd LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
CN114716533B (zh) * 2022-04-12 2023-04-14 北京惠之衡生物科技有限公司 一种酰化的长效glp-1衍生物
US20250250269A1 (en) 2022-04-14 2025-08-07 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4622998A2 (en) * 2022-11-21 2025-10-01 Eli Lilly and Company Process for preparing a gip/glp1 dual agonist
WO2024158668A1 (en) * 2023-01-23 2024-08-02 CrossChem Limited Compounds for use in keratin treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2100671C (en) 1991-02-27 1999-02-02 James S. Huston Serine rich peptide linkers
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
CA2136078A1 (en) * 1992-12-04 1994-06-23 Jonathan Greer 6-position modified decapeptide lhrh antagonists
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5663907A (en) 1996-04-25 1997-09-02 Bright Microelectronics, Inc. Switch driver circuit for providing small sector sizes for negative gate erase flash EEPROMS using a standard twin-well CMOS process
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
EP1060191B1 (en) * 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU757658B2 (en) 1998-03-09 2003-02-27 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SI1724284T1 (sl) 2000-12-07 2009-12-31 Lilly Co Eli Glp-1 fuzijski proteini
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
EP1750754A4 (en) 2004-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100317057A1 (en) 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
US20120329711A1 (en) * 2009-12-16 2012-12-27 Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
JP6231386B2 (ja) 2010-11-09 2017-11-15 ノヴォ ノルディスク アー/エス リンカーを有する二重アシル化されたglp−1誘導体
EP2846823B1 (en) 2012-05-08 2019-12-04 Novo Nordisk A/S Double-acylated glp-1 derivatives
CN104411322B (zh) 2012-05-08 2017-05-24 诺和诺德股份有限公司 双酰化glp‑1衍生物

Similar Documents

Publication Publication Date Title
JP2013543853A5 (enExample)
JP2014501712A5 (enExample)
RU2013148921A (ru) Дважды ацилированные производные glp-1
JP2015517478A5 (enExample)
JP2017514801A5 (enExample)
JP2015517477A5 (enExample)
JP2016523243A5 (enExample)
JP2017105819A5 (enExample)
JP2016529253A5 (enExample)
JP2013517307A5 (enExample)
JP2014503526A5 (enExample)
US11167014B2 (en) Solid glp-1 derivative compositions for oral administration
JP2018506507A5 (enExample)
JP2008533105A5 (enExample)
JP2005528337A5 (enExample)
JP7432361B2 (ja) ヒトインスリンまたはそのアナログのアシル化誘導体
JP2019513126A5 (enExample)
JP2016526012A5 (enExample)
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
JP2010529004A5 (enExample)
JP2010515677A5 (enExample)
RU2012128547A (ru) Дважды ацилированные производные glp-1
JP2015517459A5 (enExample)
JP2008533104A (ja) Glp−1受容体の二量体ペプチドアゴニスト
CN103189389A (zh) 新的glp-ⅰ类似物及其制备方法和用途